- Home
- STKS vs CRDL Comparison
STKS vs CRDL Comparison
Compare STKS & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- CRDL
- Stock Information
- Founded
- STKS 2004
- CRDL 2017
- Country
- STKS United States
- CRDL Canada
- Employees
- STKS N/A
- CRDL N/A
- Industry
- STKS Restaurants
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STKS Consumer Discretionary
- CRDL Health Care
- Exchange
- STKS Nasdaq
- CRDL Nasdaq
- Market Cap
- STKS 100.6M
- CRDL 102.0M
- IPO Year
- STKS N/A
- CRDL N/A
- Fundamental
- Price
- STKS $2.99
- CRDL $0.96
- Analyst Decision
- STKS Buy
- CRDL Strong Buy
- Analyst Count
- STKS 2
- CRDL 3
- Target Price
- STKS $4.25
- CRDL $9.00
- AVG Volume (30 Days)
- STKS 73.4K
- CRDL 243.4K
- Earning Date
- STKS 03-10-2025
- CRDL 05-13-2025
- Dividend Yield
- STKS N/A
- CRDL N/A
- EPS Growth
- STKS N/A
- CRDL N/A
- EPS
- STKS N/A
- CRDL N/A
- Revenue
- STKS $673,344,000.00
- CRDL N/A
- Revenue This Year
- STKS $28.47
- CRDL N/A
- Revenue Next Year
- STKS N/A
- CRDL N/A
- P/E Ratio
- STKS N/A
- CRDL N/A
- Revenue Growth
- STKS 102.35
- CRDL N/A
- 52 Week Low
- STKS $2.37
- CRDL $0.91
- 52 Week High
- STKS $6.10
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- STKS 52.53
- CRDL 34.61
- Support Level
- STKS $2.83
- CRDL $1.10
- Resistance Level
- STKS $3.04
- CRDL $1.18
- Average True Range (ATR)
- STKS 0.18
- CRDL 0.09
- MACD
- STKS 0.05
- CRDL -0.01
- Stochastic Oscillator
- STKS 92.54
- CRDL 14.78
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Kona Grill, ONE Hospitality, and Corporate. The company generates the vast majority of its revenue from the domestic market.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.